GI Drugs Flashcards
Learn Class, MOA, Adverse Effects/Unique Features
Aluminum salts
Class: Low-systemic antacid
MOA: binds luminal H+ to produce H2O, CO2, or Cl- salts
Adverse Effects: Constipation, Hypophospatemia
Calcium salts
Class: Low-systemic antacid
MOA: binds luminal H+ to produce H2O, CO2, or Cl- salts
Adverse Effects: Constipation, hypercalcemia, hypophosphatemia, calcium-based kidney stones
Magnesium salts
Class: Low-systemic antacid
MOA: binds luminal H+ to produce H2O, CO2, or Cl- salts
Adverse Effects: Diarrhea, hypermagnesemia
Sodium salts
Class: high-systemic antacid
MOA: Binds luminal H+ to produce H2O, CO2, or Cl- salts
Adverse Effects: Gas/flatulence, hypernatremia, metabolic alkalosis
Simethicone
Class: Supplemental antacid
MOA: surfactant that decreases surface tension of gas bubbles in the GI tract to create one, easily passable gas bubble
Adverse Effects: none listed
Cimetidine
Class: H2 receptor antagonist
MOA: Reversibly inhibits H2-receptors on the basolateral membrane of parietal cells
Adverse Effects: Nausea, diarrhea, constipation, headache
Unique characteristics: gynechomastia in men, galactorrhea in women, neutropenia, thrombocytopenia, prototypical CYP450 inhibitor
Famotidine
Class: H2 receptor antagonist
MOA: Reversibly inhibits H2-receptors on the basolateral membrane of parietal cells
Adverse Effects: Nausea, diarrhea, constipation, headache
Nizatidine
Class: H2 receptor antagonist
MOA: Reversibly inhibits H2-receptors on the basolateral membrane of parietal cells
Adverse Effects: Nausea, diarrhea, constipation, headache
Ranitidine
Class: H2 receptor antagonist
MOA: Reversibly inhibits H2-receptors on the basolateral membrane of parietal cells
Adverse Effects: Nausea, diarrhea, constipation, headache
Lansoprazole
Class: Proton pump inhibitors
MOA: irreversibly binds sulfhydryl groups of H/K-ATPase at parietal cell secretory sites, inhibiting gastric acid secretion
Adverse Effects: Nausea, diarrhea, dyspepsia, increased risk for C diff infection, HA, dizziness
Dexlansoprazole
Class: Proton pump inhibitors
MOA: irreversibly binds sulfhydryl groups of H/K-ATPase at parietal cell secretory sites, inhibiting gastric acid secretion
Adverse Effects: Nausea, diarrhea, dyspepsia, increased risk for C diff infection, HA, dizziness
Omeprazole
Class: Proton pump inhibitors
MOA: irreversibly binds sulfhydryl groups of H/K-ATPase at parietal cell secretory sites, inhibiting gastric acid secretion
Adverse Effects: Nausea, diarrhea, dyspepsia, increased risk for C diff infection, HA, dizziness
Unique Characteristics: prototypical CYP450 inhibitor
Esomeprazole
Class: Proton pump inhibitors
MOA: irreversibly binds sulfhydryl groups of H/K-ATPase at parietal cell secretory sites, inhibiting gastric acid secretion
Adverse Effects: Nausea, diarrhea, dyspepsia, increased risk for C diff infection, HA, dizziness
Pantoprazole
Class: Proton pump inhibitors
MOA: irreversibly binds sulfhydryl groups of H/K-ATPase at parietal cell secretory sites, inhibiting gastric acid secretion
Adverse Effects: Nausea, diarrhea, dyspepsia, increased risk for C diff infection, HA, dizziness
Rabeprazole
Class: Proton pump inhibitors
MOA: irreversibly binds sulfhydryl groups of H/K-ATPase at parietal cell secretory sites, inhibiting gastric acid secretion
Adverse Effects: Nausea, diarrhea, dyspepsia, increased risk for C diff infection, HA, dizziness
Sucralfate
Class: Surface acting anti-ulcer agent
MOA: cross-links w/ itself in response to stomach acid to create a sticky polymer that adheres to epithelial cells around the ulcer’s crater
Adverse Effects: Constipation d/t conjugated Al(OH)3
Misoprostol
Class: misoprostol
MOA: reduces gastric acid release from parietal cells and stimulates cytoprotective actions of gastric mucosa
Adverse Effects: diarrhea, cramping, HA, dizziness
Bismuth subsalicylate
Class: bismuth antiulcer agents
MOA: prevents microbial attachment to mucosa, inactivates enterotoxins, disrupts bacterial cell wall
Adverse Effects: constipation, black regularly formed stools
Dolasetron
Class: Serotonin Receptor Antagonist
MOA: blocks serotonin receptors at vagal nerve terminals and block signal transmission to CTZ
Adverse Effects: HA, constipation/diarrhea, serotonin syndrome, QT prolongation, Torsade de pointes
Granisetron
Class: Serotonin Receptor Antagonist
MOA: blocks serotonin receptors at vagal nerve terminals and block signal transmission to CTZ
Adverse Effects: HA, constipation/diarrhea, serotonin syndrome, QT prolongation, Torsade de pointes
Unique characteristic: sustained-release allows for once daily administration
Ondansetron
Class: Serotonin Receptor Antagonist
MOA: blocks serotonin receptors at vagal nerve terminals and block signal transmission to CTZ
Adverse Effects: HA, constipation/diarrhea, serotonin syndrome, QT prolongation, Torsade de pointes
Palonosetron
Class: Serotonin Receptor Antagonist
MOA: blocks serotonin receptors at vagal nerve terminals and block signal transmission to CTZ
Adverse Effects: HA, constipation/diarrhea, serotonin syndrome, QT prolongation, Torsade de pointes
Unique Characteristic: sustained-release allows for once daily administration
Aprepitant
Class: neurokinin-1 receptor antagonist
MOA: blocks NK1 receptors in the CTZ and vomit center
Adverse effects: dyspepsia, constipation, diarrhea, dizziness, fatigue, somnolence
Unique Characteristic: given up to 3 hours prior to anesthesia induction to control vomiting
Fosaprepitant
Class: neurokinin-1 receptor antagonist
MOA: blocks NK1 receptors in the CTZ and vomit center
Adverse effects: dyspepsia, constipation, diarrhea, dizziness, fatigue, somnolence
Netupitant
Class: neurokinin-1 receptor antagonist
MOA: blocks NK1 receptors in the CTZ and vomit center
Adverse effects: dyspepsia, constipation, diarrhea, dizziness, fatigue, somnolence
Unique characteristic: longer half-life
Fosnetupitant
Class: neurokinin-1 receptor antagonist
MOA: blocks NK1 receptors in the CTZ and vomit center
Adverse effects: dyspepsia, constipation, diarrhea, dizziness, fatigue, somnolence
Unique characteristic: longer half-life
Rolapitant
Class: neurokinin-1 receptor antagonist
MOA: blocks NK1 receptors in the CTZ and vomit center
Adverse effects: dyspepsia, constipation, diarrhea, dizziness, fatigue, somnolence
Diphenhydramine
Class: Histamine-1 Receptor Antagonist
MOA: blocks H1 receptors in the VC and vestibular system
Adverse effects: Drowsiness, dry mouth, constipation, urinary retention, blurred vision, decreased BP
Dimenhydrinate
Class: Histamine-1 Receptor Antagonist
MOA: blocks H1 receptors in the VC and vestibular system
Adverse effects: Drowsiness, dry mouth, constipation, urinary retention, blurred vision, decreased BP
Hydroxyzine
Class: Histamine-1 Receptor Antagonist
MOA: blocks H1 receptors in the VC and vestibular system
Adverse effects: Drowsiness, dry mouth, constipation, urinary retention, blurred vision, decreased BP
Promethazine
Class: Histamine-1 Receptor Antagonist
MOA: blocks H1 receptors in the VC and vestibular system
Adverse effects: Drowsiness, dry mouth, constipation, urinary retention, blurred vision, decreased BP
Meclizine
Class: Histamine-1 Receptor Antagonist
MOA: blocks H1 receptors in the VC and vestibular system
Adverse effects: Drowsiness, dry mouth, constipation, urinary retention, blurred vision, decreased BP
Cyclizine
Class: Histamine-1 Receptor Antagonist
MOA: blocks H1 receptors in the VC and vestibular system
Adverse effects: Drowsiness, dry mouth, constipation, urinary retention, blurred vision, decreased BP
Doxylamine
Class: Histamine-1 Receptor Antagonist
MOA: blocks H1 receptors in the VC and vestibular system
Adverse effects: Drowsiness, dry mouth, constipation, urinary retention, blurred vision, decreased BP
Chlorpromazine
Class: Phenothiazine Dopamine-2 receptor antagonist
MOA: blocks D2 receptors in the CTZ
Adverse Effects: Drowsiness, dry mouth, constipation, urinary retention, blurred vision, arrhythmias
Perphenazine
Class: Phenothiazine Dopamine-2 receptor antagonist
MOA: blocks D2 receptors in the CTZ
Adverse Effects: Drowsiness, dry mouth, constipation, urinary retention, blurred vision, arrhythmias